Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Sevasemten

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Edgewise to Show Sevasemten Data for Becker, Duchenne Dystrophy
    Edgewise to Show Sevasemten Data for Becker, Duchenne Dystrophy

    02 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-on-sevasemten-for-becker-and-duchenne-muscular-dystrophies-at-the-30th-international-annual-congress-of-the-world-muscle-society-302573117.html

    PR NEWSWIRE
    02 Oct 2025
    Share Share
    Edgewise Therapeutics Reports Q2 2025 Financials and Business
    Edgewise Therapeutics Reports Q2 2025 Financials and Business

    08 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business-highlights-302523640.html

    PR NEWSWIRE
    08 Aug 2025
    Share Share
    Edgewise Gets EMA Orphan Designation for Muscular Dystrophies Drug
    Edgewise Gets EMA Orphan Designation for Muscular Dystrophies Drug

    23 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240423844146/en

    BUSINESSWIRE
    23 Apr 2024
    Share Share
    Edgewise Positive 2-Year Becker Sevasemten Topline Data
    Edgewise Positive 2-Year Becker Sevasemten Topline Data

    15 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240415221564/en

    BUSINESSWIRE
    15 Apr 2024
    Share Share